^
Association details:
| Biomarker: | HR positive + TMB-L |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | fulvestrant (Selective estrogen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China
Published date:
09/23/2020
Excerpt:
In total 303 enrolled patients [median age was 51 years (range: 21-82)], 255 (84.2%) patients were at postmenopausal status at the start of Fulvestrant treatment and 264 patients (87.1%) had advanced breast cancer...The multivariate subgroup analyses showed, PFS was significantly longer for the patients with light tumor burden, less palliative chemotherapy before Fulvestrant and long disease-free interval....Fulvestrant is an effective, safe and well-tolerated treatment regimen in endocrine therapy for HR+/HER2- metastatic breast cancer.
DOI:
10.7150/jca.47960
